1062 related articles for article (PubMed ID: 30729688)
1. Clinical significance of positive anti-neutrophil cytoplasmic antibodies without evidence of anti-neutrophil cytoplasmic antibodies-associated vasculitis.
Bornstein G; Ben-Zvi I; Furie N; Grossman C
Int J Rheum Dis; 2019 May; 22(5):940-945. PubMed ID: 30729688
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics of patients with vasculitis positive for anti-neutrophil cytoplasmic antibody targeting both proteinase 3 and myeloperoxidase: a retrospective study.
Kim SM; Choi SY; Kim SY; Kim J
Rheumatol Int; 2019 Nov; 39(11):1919-1926. PubMed ID: 31552433
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of different commercial ELISA systems for the detection of anti-neutrophil cytoplasm antibodies in ANCA-associated vasculitides.
Holle JU; Herrmann K; Gross WL; Csernok E
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S66-9. PubMed ID: 22512915
[TBL] [Abstract][Full Text] [Related]
4. Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Berti A; Warner R; Johnson K; Cornec D; Schroeder D; Kabat B; Langford CA; Hoffman GS; Fervenza FC; Kallenberg CGM; Seo P; Spiera R; St Clair EW; Brunetta P; Stone JH; Merkel PA; Specks U; Monach PA;
Arthritis Rheumatol; 2018 Jul; 70(7):1114-1121. PubMed ID: 29693324
[TBL] [Abstract][Full Text] [Related]
5. The performance of the chemiluminescent immunoassay for measuring serum myeloperoxidase and proteinase 3 antibodies.
Hou X; Liu J; Wang T; Zhou J; Cui L
J Clin Lab Anal; 2021 Feb; 35(2):e23615. PubMed ID: 33034910
[TBL] [Abstract][Full Text] [Related]
6. Distinction between MPO-ANCA and PR3-ANCA-associated glomerulonephritis in Chinese patients: a retrospective single-center study.
Hong Y; Shi P; Liu X; Yang L; Li K; Xu F; Liang S; Liu Z; Zhang H; Chen Y; Hu W
Clin Rheumatol; 2019 Jun; 38(6):1665-1673. PubMed ID: 30737591
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization.
Hagen EC; Daha MR; Hermans J; Andrassy K; Csernok E; Gaskin G; Lesavre P; Lüdemann J; Rasmussen N; Sinico RA; Wiik A; van der Woude FJ
Kidney Int; 1998 Mar; 53(3):743-53. PubMed ID: 9507222
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
9. Myeloperoxidase anti-neutrophil cytoplasmic antibody affinity is associated with the formation of neutrophil extracellular traps in the kidney and vasculitis activity in myeloperoxidase anti-neutrophil cytoplasmic antibody-associated microscopic polyangiitis.
Yoshida M; Yamada M; Sudo Y; Kojima T; Tomiyasu T; Yoshikawa N; Oda T; Yamada M
Nephrology (Carlton); 2016 Jul; 21(7):624-9. PubMed ID: 26833773
[TBL] [Abstract][Full Text] [Related]
10. Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis.
Moxey J; Huq M; Proudman S; Sahhar J; Ngian GS; Walker J; Strickland G; Wilson M; Ross L; Major G; Roddy J; Stevens W; Nikpour M
Arthritis Res Ther; 2019 Feb; 21(1):57. PubMed ID: 30764870
[TBL] [Abstract][Full Text] [Related]
11. Difference in relapse-rate and clinical phenotype by autoantibody-subtype in Japanese patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
Murosaki T; Sato T; Akiyama Y; Nagatani K; Minota S
Mod Rheumatol; 2017 Jan; 27(1):95-101. PubMed ID: 27320904
[TBL] [Abstract][Full Text] [Related]
12. Myeloperoxidase-antineutrophil Cytoplasmic Antibodies (MPO-ANCA) and Proteinase 3-ANCA without Immunofluorescent ANCA Found by Routine Clinical Testing.
Rao DA; Wei K; Merola JF; O'Brien WR; Takvorian SU; Dellaripa PF; Schur PH
J Rheumatol; 2015 May; 42(5):847-52. PubMed ID: 25834211
[TBL] [Abstract][Full Text] [Related]
13. Presence of dual anti-MPO and anti-PR3 antibodies in Systemic Lupus Erythematosus/ANCA-Associated Vasculitis.
Fernando SL; Boyle T
J Clin Pathol; 2020 Oct; 73(10):687-688. PubMed ID: 32513843
[No Abstract] [Full Text] [Related]
14. Comparison of a novel chemiluminescence enzyme immunoassay (CLEIA) with enzyme-linked immunosorbent assay (ELISA) for the determination of MPO-ANCA in patients with ANCA-associated vasculitis.
Hirose O; Itabashi M; Takei T; Nitta K
Mod Rheumatol; 2015 Mar; 25(2):230-4. PubMed ID: 25388618
[TBL] [Abstract][Full Text] [Related]
15. Antibody subtypes and titers predict clinical outcomes in ANCA-associated vasculitis.
Aljuhani M; Makati D; Hoff A; Thompson J; Pellegrino B; Shawwa K; Schmidt R; Kannabhiran D
Rheumatol Int; 2021 May; 41(5):965-972. PubMed ID: 33585954
[TBL] [Abstract][Full Text] [Related]
16. Prolonged infections associated with antineutrophil cytoplasmic antibodies specific to proteinase 3 and myeloperoxidase: diagnostic and therapeutic challenge.
Bonaci-Nikolic B; Andrejevic S; Pavlovic M; Dimcic Z; Ivanovic B; Nikolic M
Clin Rheumatol; 2010 Aug; 29(8):893-904. PubMed ID: 20306213
[TBL] [Abstract][Full Text] [Related]
17. A critical evaluation of commercial immunoassays for antineutrophil cytoplasmic antibodies directed against proteinase 3 and myeloperoxidase in Wegener's granulomatosis and microscopic polyangiitis.
Csernok E; Ahlquist D; Ullrich S; Gross WL
Rheumatology (Oxford); 2002 Nov; 41(11):1313-7. PubMed ID: 12422006
[TBL] [Abstract][Full Text] [Related]
18. A multicentre study to improve clinical interpretation of proteinase-3 and myeloperoxidase anti-neutrophil cytoplasmic antibodies.
Bossuyt X; Rasmussen N; van Paassen P; Hellmich B; Baslund B; Vermeersch P; Blockmans D; Cohen Tervaert JW; Csernok E; Damoiseaux J
Rheumatology (Oxford); 2017 Sep; 56(9):1533-1541. PubMed ID: 28541581
[TBL] [Abstract][Full Text] [Related]
19. IgG from myeloperoxidase-antineutrophil cytoplasmic antibody-positive patients stimulates greater activation of primed neutrophils than IgG from proteinase 3-antineutrophil cytosplasmic antibody-positive patients.
Harper L; Radford D; Plant T; Drayson M; Adu D; Savage CO
Arthritis Rheum; 2001 Apr; 44(4):921-30. PubMed ID: 11315931
[TBL] [Abstract][Full Text] [Related]
20. ANCA testing: the current stage and perspectives.
Csernok E
Clin Exp Nephrol; 2013 Oct; 17(5):615-618. PubMed ID: 23180043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
